Estimated burden of fungal infections in Panama

IF 2.2 4区 医学 Q3 MYCOLOGY
Cristel Rodríguez-Vargas , Ana Alastruey-Izquierdo , David W. Denning , Ana Belén Araúz
{"title":"Estimated burden of fungal infections in Panama","authors":"Cristel Rodríguez-Vargas ,&nbsp;Ana Alastruey-Izquierdo ,&nbsp;David W. Denning ,&nbsp;Ana Belén Araúz","doi":"10.1016/j.mycmed.2024.101466","DOIUrl":null,"url":null,"abstract":"<div><p>Data published on Panamanian fungal disease are scarce, mostly case reports. To date, there is no paper that compiles the burden of fungal disease Here we estimate for the first time the incidence and prevalence of fungal diseases in Panama. Data on fungal disease were obtained from different search engines: PubMed, Google Scholar, Scielo and Lilacs. For population and at risk diseases, we used statistics from worldometer, UNAIDS, and WHO. Incidence, prevalence, and absolute numbers were calculated based on the population at risk. Panamanian population in 2022 was 4,429,739. We estimated that 85,530 (1.93 %) people suffer from fungal diseases. The most frequent fungal infection was recurrent <em>Candida</em> vaginitis (3320/100,000). There are 31,000 HIV-infected people in Panama and based on the number of cases not receiving anti-retroviral therapy (14,570), and previous reports of prevalence of opportunistic infections, we estimated annual incidences of 4.0/100,000 for cryptococcal meningitis, 29.6/100,000 for oral candidiasis, 23.2/100,000 for esophageal candidiasis, 29.3/100,000 for <em>Pneumocystis</em> pneumonia, 15.1/100,000, and for histoplasmosis. For chronic pulmonary aspergillosis (CPA) and fungal asthma we used data from Guatemala and Colombia to estimate COPD and asthma prevalence and WHO report for tuberculosis. We estimated annual incidences of 6.1/100,000 for invasive aspergillosis and prevalence of 31.7/100,000 for CPA, 60.5/100,000 for allergic bronchopulmonary aspergillosis, and 79.9/100,000 for severe asthma with fungal sensitisation. Other incidence estimates were 5.0/100,000 for candidaemia, 0.20/100,000 for mucormycosis, and 4.99/100,000 for fungal keratitis. Even though this report on burden of fungal disease is a forward step, more epidemiological studies to validate these estimates are needed.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"34 1","pages":"Article 101466"},"PeriodicalIF":2.2000,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1156523324000076/pdfft?md5=0a35aee58e89374e39772a23c65fdc21&pid=1-s2.0-S1156523324000076-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal de mycologie medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1156523324000076","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MYCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Data published on Panamanian fungal disease are scarce, mostly case reports. To date, there is no paper that compiles the burden of fungal disease Here we estimate for the first time the incidence and prevalence of fungal diseases in Panama. Data on fungal disease were obtained from different search engines: PubMed, Google Scholar, Scielo and Lilacs. For population and at risk diseases, we used statistics from worldometer, UNAIDS, and WHO. Incidence, prevalence, and absolute numbers were calculated based on the population at risk. Panamanian population in 2022 was 4,429,739. We estimated that 85,530 (1.93 %) people suffer from fungal diseases. The most frequent fungal infection was recurrent Candida vaginitis (3320/100,000). There are 31,000 HIV-infected people in Panama and based on the number of cases not receiving anti-retroviral therapy (14,570), and previous reports of prevalence of opportunistic infections, we estimated annual incidences of 4.0/100,000 for cryptococcal meningitis, 29.6/100,000 for oral candidiasis, 23.2/100,000 for esophageal candidiasis, 29.3/100,000 for Pneumocystis pneumonia, 15.1/100,000, and for histoplasmosis. For chronic pulmonary aspergillosis (CPA) and fungal asthma we used data from Guatemala and Colombia to estimate COPD and asthma prevalence and WHO report for tuberculosis. We estimated annual incidences of 6.1/100,000 for invasive aspergillosis and prevalence of 31.7/100,000 for CPA, 60.5/100,000 for allergic bronchopulmonary aspergillosis, and 79.9/100,000 for severe asthma with fungal sensitisation. Other incidence estimates were 5.0/100,000 for candidaemia, 0.20/100,000 for mucormycosis, and 4.99/100,000 for fungal keratitis. Even though this report on burden of fungal disease is a forward step, more epidemiological studies to validate these estimates are needed.

巴拿马真菌感染的估计负担
有关巴拿马真菌病的数据很少,大多是病例报告。在此,我们首次对巴拿马真菌病的发病率和流行率进行了估算。有关真菌病的数据来自不同的搜索引擎:PubMed、Google Scholar、Scielo 和 Lilacs。在人口和高危疾病方面,我们使用了来自 worldometer、联合国艾滋病规划署和世界卫生组织的统计数据。发病率、流行率和绝对数是根据高危人群计算得出的。2022 年巴拿马人口为 4,429,739 人。据估计,有 85,530 人(1.93%)患有真菌疾病。最常见的真菌感染是复发性念珠菌阴道炎(3320/100000)。巴拿马有 31,000 名艾滋病毒感染者,根据未接受抗逆转录病毒治疗的病例数(14,570 例)和以往关于机会性感染发病率的报告,我们估计隐球菌性脑膜炎的年发病率为 4.0/100,000,口腔念珠菌病为 29.6/100,000,食道念珠菌病为 23.2/100,000,肺孢子菌肺炎为 29.3/100,000,组织胞浆菌病为 15.1/100,000。对于慢性肺曲霉菌病(CPA)和真菌性哮喘,我们使用了危地马拉和哥伦比亚的数据来估算慢性阻塞性肺病和哮喘的发病率,并使用了世界卫生组织的结核病报告。我们估计侵袭性曲霉菌病的年发病率为 6.1/100,000,CPA 的年发病率为 31.7/100,000,过敏性支气管肺曲霉菌病的年发病率为 60.5/100,000,真菌过敏性重症哮喘的年发病率为 79.9/100,000。其他发病率估计分别为:念珠菌血症 5.0/100,000,粘孢子菌病 0.20/100,000,真菌性角膜炎 4.99/100,000。尽管这份关于真菌疾病负担的报告是向前迈出的一步,但还需要更多的流行病学研究来验证这些估计值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.10
自引率
2.80%
发文量
68
审稿时长
6-12 weeks
期刊介绍: The Journal de Mycologie Medicale / Journal of Medical Mycology (JMM) publishes in English works dealing with human and animal mycology. The subjects treated are focused in particular on clinical, diagnostic, epidemiological, immunological, medical, pathological, preventive or therapeutic aspects of mycoses. Also covered are basic aspects linked primarily with morphology (electronic and photonic microscopy), physiology, biochemistry, cellular and molecular biology, immunochemistry, genetics, taxonomy or phylogeny of pathogenic or opportunistic fungi and actinomycetes in humans or animals. Studies of natural products showing inhibitory activity against pathogenic fungi cannot be considered without chemical characterization and identification of the compounds responsible for the inhibitory activity. JMM publishes (guest) editorials, original articles, reviews (and minireviews), case reports, technical notes, letters to the editor and information. Only clinical cases with real originality (new species, new clinical present action, new geographical localization, etc.), and fully documented (identification methods, results, etc.), will be considered. Under no circumstances does the journal guarantee publication before the editorial board makes its final decision. The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信